FM, Roche and DIAN collaborate for Personalized Cancer Care in China
Foundation Medicine, Inc. (FM), F. Hoffmann-La Roche Ltd (Roche) and DIAN Diagnostics Group, Co., Ltd. (DIAN), have announced a three-party collaboration to integrate Foundation Medicine’s comprehensive genomic profiling (CGP) assays into clinical patient care in mainland China.
Under the collaboration, DIAN, a leader in the development and supply of Chinese medical diagnostic products and services, becomes the exclusive clinical sequencing partner in China for FoundationOne, FoundationACT and FoundationOneHeme, enabling the delivery of personalized cancer care for patients. Roche maintains commercial exclusivity for Foundation Medicine’s molecular information products in China, and in cooperation with DIAN continues its current in-county activities to support the broad integration of CGP into clinical care.
DIAN is one of the leading independent medical laboratories in China and is dedicated to innovation in diagnostic testing platforms. Importantly, DIAN is one of the first commercial laboratories approved by the National Health Commission of China to receive a next generation sequencing (NGS) pilot license for cancer diagnostics. DIAN’s diagnostic network stretches to more than 30 laboratories, covering almost all of mainland China, processing more than 100,000 clinical samples per day. To advance clinical diagnostics in China, DIAN has also established precision treatment centres with medical institutions and hospitals.